Real-world GLP-1 series reports 11.3% weight loss, 1.46 kg muscle decline

The wire

1. 01A retrospective study in Endocrine Practice followed 388 adults with obesity on GLP-1 receptor agonists for six months, finding 11.3% mean weight loss, an 8.95% fat mass reduction and a 1.46 kg skeletal muscle decrease.
2. 02Clinicians debating muscle loss on incretin therapy get real-world bioimpedance figures, and the authors argue for body composition assessment beyond BMI in obesity management.
3. 03Adherent patients lost more fat than nonadherent ones. The study is retrospective, single-clinic and uses bioelectrical impedance, which is less precise than DXA.

From the source

Changes in Body Composition Assessed by Bioelectrical Impedance Analysis in Patients Treated with GLP-1 Receptor Agonists: A Real-World Experience

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026 Sep 19 · Goñi JA, Barba MS, López GP et al.